Search - tctmd.com

Displaying 1 - 20 of 82

Sort: Relevancy | Date

News Daily News

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

Yael L. Maxwell

October 23, 2025

News Daily News

Higher Lp(a) Indicates Greater Chance of Stenosis on CCTA in Patients With Chest Pain

Yael L. Maxwell

January 13, 2025

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Caitlin E. Cox

November 21, 2024

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News Daily News

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Yael L. Maxwell

June 26, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

News Daily News

Half of American Indian and Alaska Native Seniors Have CVD: Medicare Analysis

L.A. McKeown

September 25, 2023

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Daily News

Statin Therapy Still Lacking for Many US Patients With ASCVD

L.A. McKeown

August 07, 2023

News Daily News

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

Michael O'Riordan

July 28, 2023

News Daily News

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Michael O'Riordan

July 25, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

Presentation ACC 2023

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Presenter: Annapoorna S. Kini

March 06, 2023

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

Advertisement

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

Higher Lp(a) Indicates Greater Chance of Stenosis on CCTA in Patients With Chest Pain

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Half of American Indian and Alaska Native Seniors Have CVD: Medicare Analysis

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Statin Therapy Still Lacking for Many US Patients With ASCVD

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

LDL Control Remains Poor in CAD Patients: NHANES

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Good News and Bad for High-Intensity Statin Use in ASCVD

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content